CN113383074A - Caix特异性的双环肽配体 - Google Patents

Caix特异性的双环肽配体 Download PDF

Info

Publication number
CN113383074A
CN113383074A CN202080009486.9A CN202080009486A CN113383074A CN 113383074 A CN113383074 A CN 113383074A CN 202080009486 A CN202080009486 A CN 202080009486A CN 113383074 A CN113383074 A CN 113383074A
Authority
CN
China
Prior art keywords
seq
referred
iii
sar
peptide ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080009486.9A
Other languages
English (en)
Chinese (zh)
Inventor
L·巴尔达萨雷
L·陈
R·拉尼
C·斯泰斯
D·托伊费尔
E·沃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bicycle Therapeutics PLC
Original Assignee
Bicycle Therapeutics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycle Therapeutics PLC filed Critical Bicycle Therapeutics PLC
Publication of CN113383074A publication Critical patent/CN113383074A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01001—Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080009486.9A 2019-01-15 2020-01-15 Caix特异性的双环肽配体 Pending CN113383074A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1900526.3 2019-01-15
GBGB1900526.3A GB201900526D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for caix
PCT/GB2020/050070 WO2020148526A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for caix

Publications (1)

Publication Number Publication Date
CN113383074A true CN113383074A (zh) 2021-09-10

Family

ID=65528170

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080009486.9A Pending CN113383074A (zh) 2019-01-15 2020-01-15 Caix特异性的双环肽配体

Country Status (6)

Country Link
US (1) US20220133732A1 (cg-RX-API-DMAC7.html)
EP (1) EP3911743A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022517442A (cg-RX-API-DMAC7.html)
CN (1) CN113383074A (cg-RX-API-DMAC7.html)
GB (1) GB201900526D0 (cg-RX-API-DMAC7.html)
WO (1) WO2020148526A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117120458A (zh) * 2022-02-11 2023-11-24 C-比奥麦克斯有限公司 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途
WO2024041535A1 (zh) * 2022-08-22 2024-02-29 赣州和美药业股份有限公司 纳米组合物及其制备方法和用途
CN120230182A (zh) * 2025-05-29 2025-07-01 北京肿瘤医院(北京大学肿瘤医院) 经修饰的caix靶向环肽及其核素标记物与应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
EP4448544A2 (en) 2021-12-17 2024-10-23 3B Pharmaceuticals GmbH Carbonic anhydrase ix ligands

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191460A1 (en) * 2016-05-04 2017-11-09 Bicycle Therapeutics Limited Bicyclic peptide-toxin conjugates specific for mt1-mmp
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
ES2428869T3 (es) 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
EP3615550A1 (en) * 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191460A1 (en) * 2016-05-04 2017-11-09 Bicycle Therapeutics Limited Bicyclic peptide-toxin conjugates specific for mt1-mmp
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117120458A (zh) * 2022-02-11 2023-11-24 C-比奥麦克斯有限公司 靶向碳酸酐酶ix的肽配体、包含其的肽结构体及它们的用途
WO2024041535A1 (zh) * 2022-08-22 2024-02-29 赣州和美药业股份有限公司 纳米组合物及其制备方法和用途
CN120230182A (zh) * 2025-05-29 2025-07-01 北京肿瘤医院(北京大学肿瘤医院) 经修饰的caix靶向环肽及其核素标记物与应用

Also Published As

Publication number Publication date
JP2022517442A (ja) 2022-03-08
WO2020148526A1 (en) 2020-07-23
EP3911743A1 (en) 2021-11-24
GB201900526D0 (en) 2019-03-06
US20220133732A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
CN113383007A (zh) Caix特异性的双环肽配体
JP7658902B2 (ja) Pd-l1に特異的な二環式ペプチドリガンド
JP7460523B2 (ja) EphA2に特異的な二環ペプチドリガンド
US10994019B2 (en) Bicyclic peptide-toxin conjugates specific for MT1-MMP
CN113507960A (zh) Psma特异性的双环肽配体
CN113613728A (zh) 整联蛋白αvβ3特异性的双环肽配体
CN113543813B (zh) Cd38特异性的双环肽配体
WO2020148526A1 (en) Bicyclic peptide ligands specific for caix
CN113439088A (zh) 整联蛋白αvβ3特异性的双环肽配体
CN114521197A (zh) 异串联双环肽复合物
CN113474045A (zh) Pd-l1特异性的双环肽配体
CN114787197A (zh) 修饰的多聚双环肽配体
CN113811541A (zh) Ox40特异性的双环肽配体
CN112585157A (zh) 用于结合整联蛋白αvβ3的肽配体
CN113518648A (zh) Mt1-mmp特异性的双环肽配体
CN113474046A (zh) Il-17特异性的双环肽配体
CN113507961A (zh) FAPα特异性的双环肽配体
CN114829376A (zh) Il-17特异性的双环肽配体
CN114867736A (zh) Il-17特异性的双环肽配体
CN114787176A (zh) Il-17特异性的双环肽配体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210910

WD01 Invention patent application deemed withdrawn after publication